Affiliations: [a] Department of Medical Translational Sciences, Federico II University of Naples, Naples, Italy | [b] “Salvatore Maugeri” Foundation – IRCCS – Institute of Telese Terme (BN), Italy | [c] Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy
Correspondence:
[*]
Correspondence to: Dr. Giuseppe Rengo, MD, PhD, “Salvatore Maugeri” Foundation – IRCCS – Institute of Telese Terme (BN), Via Bagni Vecchi 1, 82037 Telese Terme (BN), Italy. Tel./Fax: +39 0817462267; E-mail: [email protected].
Note: [1] These authors contributed equally to this work.
Abstract: Alzheimer's disease (AD) is a devastating form of dementia that imposes a severe burden on health systems and society. Although several aspects of AD pathogenesis have been elucidated over the last few decades, many questions still need to be addressed. In fact, currently available medications only provide symptomatic improvement in patients with AD without affecting disease progression. The β-adrenergic receptor (β-AR) system can be considered a possible target that deserves further exploration in AD. The central noradrenergic system undergoes substantial changes in the course of AD and β-ARs have been implicated not only in amyloid formation in AD brain but also in amyloid-induced neurotoxicity. Moreover, clinical evidence suggests a protective role of β-AR blockers on AD onset. In addition to that, post-receptor components of β-AR signaling seem to have a role in AD pathogenesis. In particular, the G protein coupled receptor kinase 2, responsible for β-AR desensitization and downregulation, mediates amyloid-induced β-AR dysfunction in neurons, and its levels in circulating lymphocytes of AD patients are increased and inversely correlated with patient's cognitive status. Therefore, there is an urgent need to gain further insight on the role of the adrenergic system components in AD pathogenesis in order to translate preclinical and clinical knowledge to more efficacious prognostic and therapeutic strategies.
